Correlation Between Ikena Oncology and Krystal Biotech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ikena Oncology and Krystal Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ikena Oncology and Krystal Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ikena Oncology and Krystal Biotech, you can compare the effects of market volatilities on Ikena Oncology and Krystal Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ikena Oncology with a short position of Krystal Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ikena Oncology and Krystal Biotech.

Diversification Opportunities for Ikena Oncology and Krystal Biotech

-0.72
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Ikena and Krystal is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Ikena Oncology and Krystal Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Krystal Biotech and Ikena Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ikena Oncology are associated (or correlated) with Krystal Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Krystal Biotech has no effect on the direction of Ikena Oncology i.e., Ikena Oncology and Krystal Biotech go up and down completely randomly.

Pair Corralation between Ikena Oncology and Krystal Biotech

Given the investment horizon of 90 days Ikena Oncology is expected to under-perform the Krystal Biotech. But the stock apears to be less risky and, when comparing its historical volatility, Ikena Oncology is 1.2 times less risky than Krystal Biotech. The stock trades about -0.12 of its potential returns per unit of risk. The Krystal Biotech is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  15,980  in Krystal Biotech on December 29, 2024 and sell it today you would earn a total of  2,412  from holding Krystal Biotech or generate 15.09% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Ikena Oncology  vs.  Krystal Biotech

 Performance 
       Timeline  
Ikena Oncology 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Ikena Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Krystal Biotech 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Krystal Biotech unveiled solid returns over the last few months and may actually be approaching a breakup point.

Ikena Oncology and Krystal Biotech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ikena Oncology and Krystal Biotech

The main advantage of trading using opposite Ikena Oncology and Krystal Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ikena Oncology position performs unexpectedly, Krystal Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will offset losses from the drop in Krystal Biotech's long position.
The idea behind Ikena Oncology and Krystal Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Equity Valuation
Check real value of public entities based on technical and fundamental data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance